Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Revenue Recognition Changed

This revised 10Q language is very interesting.  I believe the company is saying two things:

1) some license agreements (perhaps the J settlement licenses confirmed in the 10Q) after Nov. 30 may be different from those implemented previously.  I suspect some type of ongoing payments vs. the one-time payment.

2) due to this "highly interpretive area of accounting" it has not yet been determined precisely how the revenues from these revised agreements will be recognized.

Share
New Message
Please login to post a reply